Skip to main content

Biologics

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Mar 05, 2021

Genentech announced yesterday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for the slowing the rate of decline in pulmonary function in adults SSc-ILD

Read Article

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article

Baricitinib Therapy in Covid-19 Pneumonia

Mar 04, 2021

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery. The key

Read Article

Paucity of Effectiveness Research on Telemedicine in RA

Mar 02, 2021

A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address

Read Article

NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

Mar 01, 2021

The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.

Read Article

MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients

Feb 26, 2021

The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.

Read Article
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Dr. John Cush @RheumNow( View Tweet )

Feb 26, 2021

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Feb 26, 2021

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article

Measureable Benefits to Treat-to-Target Management in RA

Feb 24, 2021

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen

Read Article

ANAGO Study - Anakinra for Gout Flare

MedPage Today
Feb 23, 2021

The interleukin (IL)-1 receptor antagonist anakinra (Kineret) was not superior to triamcinolone for relieving gout flares, but had similar effects for pain reduction as the glucocorticoid, a randomized phase II study found.

Read Article
Lung Preservation w/ Tocilizumab in Early Systemic Sclerosis Arthritis & Rheumatology has published the results of a subanalysis from TCZ clinical trials showing that Il-6 inhibition is related with preservation of lung function patients with early SSc. https://t.co/2BwWQWEkri https://t.co/pjVc8YTDwU
Dr. John Cush @RheumNow( View Tweet )
Feb 23, 2021
QD Clinics- The Sawtooth Steroid Taper Sawtooth Steroid Taper Surgery Rules for DMARDs & Biologics RA & DVT Traveling to Medical Meetings during COVID Hemoptysis and SLE When to do Genetic Testing in Febrile Patients https://t.co/dZLqGUyizG https://t.co/PYsH7K6ByB
Dr. John Cush @RheumNow( View Tweet )
Feb 23, 2021

Lung Preservation with Tocilizumab in Early Systemic Sclerosis

Feb 21, 2021

Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).

Read Article

Avacopan - Is it Really a Win for ANCA-Associated Vasculitis?

Feb 18, 2021

The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).

Read Article
On March 24, 2021 the FDA Arthritis Advisory Committee and Drug Safety .... Committees will meet online to will discuss biologics license application, for tanezumab, from Pfizer, for the proposed treatment of moderate to severe osteoarthritis in adults https://t.co/NSlutqdHzu

Dr. John Cush @RheumNow( View Tweet )

Feb 18, 2021

Weekly Semaglutide for Weight Loss in Adults

Feb 11, 2021

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.



Semaglutide, a once weekly glucagon-like

Read Article
Tofacitinib shown to work very well in ankylosing spondylitis. @RWCSmtg @JointMD https://t.co/r1yIL96HyQ
Dr. John Cush @RheumNow( View Tweet )
Feb 11, 2021
QD Clinic - Surgery Rules for DMARDs & Biologics Patient & Surgeon instructions prior to surgery https://t.co/AFSdpnxp54

Dr. John Cush @RheumNow( View Tweet )

Feb 11, 2021

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Feb 10, 2021

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the

Read Article

Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA

Feb 09, 2021

RNA sequencing and classification of RA subsets has proven useful. RNA sequencing-based stratification of RA synovial tissue showed stronger associations with clinical responses compared with histopathological classification. Additionally, for patients with low or absent B-cell lineage

Read Article
402 RA pts in RA-Paz registry, starting bDMARD betw 2000 - 2019, had 10% refractory to multiple biologics. Difficult or multi-biologic refractory Dz predicted by erosions, younger age, high baseline DAS-28, unable to lower DAS < 1.2 @6 mo (OR 11.1) https://t.co/GYJ69dgCtr

Dr. John Cush @RheumNow( View Tweet )

Feb 09, 2021
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf
Dr. John Cush @RheumNow( View Tweet )
Feb 08, 2021

IVIg in MIS-C

Feb 08, 2021

Among children with multisystem inflammatory syndrome (MIS-C), treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. MIS-C is a rare but serious pediatric condition associated with COVID-19 where different body parts can become inflamed,

Read Article
Download available--30 FDA Approved Biologics in Rheumatology https://t.co/HSvllkDUz7

Dr. John Cush @RheumNow( View Tweet )

Feb 07, 2021
PSOLAR study of 298 pregnancies in 220 women with mod-severe psoriasis. 82% resulted in live births and rates of spontaneous abortion and congenital anomalies same as US population. Biologic exposure pregnancy outcomes same as those not on biologics https://t.co/GKXyDGRILD

Dr. John Cush @RheumNow( View Tweet )

Feb 05, 2021
×